Investigational drug · Phase 2
gavo-cel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "gavo-cel"
First trial start
2019
Apr 15, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "gavo-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mesothelioma
- Mesothelioma, Malignant
- Mesothelioma; Pleura
- Mesotheliomas Pleural
- Mesothelioma Peritoneum
- Cholangiocarcinoma
- Cholangiocarcinoma Recurrent
- Ovarian Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
Approved drugs for the same conditions: Small cell lung cancer · Ovarian cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "gavo-cel" as an intervention, largest first.
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruiting
TCR2 TherapeuticsIndustry
NCT03907852 · 57 participants · Start Apr 15, 2019 · Primary completion Nov 19, 2024
Drug: gavo-cel; fludarabine and 3 more · For: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura and 8 more
Sites: San Francisco, California; Miami, Florida; Chicago, Illinois · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.
Hassan R, Butler M, O'Cearbhaill RE, et al. · Nat Med 2023
Also in development for Mesothelioma
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- ODM-212Phase 22 trials
Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer
- RSO-021ThiostreptonPhase 21 trial
RS Oncology LLC · Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma
- VMD-928Phase 21 trial
VM Oncology, LLC · Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.